Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasoc...

Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis

Benzinga Newsdesk www.benzinga.com Positive 95.6%

Neg 0% Neu 0% Pos 95.6%

Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8
More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib
Additional analyses from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance and rapid and continued improvements in patient-reported itch and quality of life